Listen
ALIMTA (pemetrexed), antimetabolite
ONCOLOGY - Focus
Opinions on drugs -
Posted on
Jun 09 2016
Reason for request
Re-assessment of the improvement in actual benefit
Moderate clinical added value in first-line treatment of unresectable malignant pleural mesothelioma
- ALIMTA has marketing authorisation, in combination with ciscplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
- It is the standard treatment for this disease.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| moderate |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
